lumateperone
Alkermes’ new antipsychotic clears FDA advisory committee hurdle
Target action date for FDA decision is due on 15 November
Troubled Alkermes eyes November OK for new antipsychotic
Review begins for potential schizophrenia and bipolar I disorder drug
Intra-Cellular soars on FDA approval of schizophrenia drug
Shares rocketed following the announcement
Karuna’s shares spike on schizophrenia drug data
Value leaps to more than $1bn following mid-stage trial results
Indivior push to diversify boosted by schizophrenia drug approval
Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna
Biogen pays $590m for Pfizer cognition drug
Early stage studies look positive for schizophrenia drug
Takeda explores the potential of ‘digital biomarkers’
Collaborates with Mindstrong Health on mental health research
Boehringer abandons PDE-targeted Alzheimer’s drug
But will keep testing the candidate in schizophrenia
Boehringer adds to pipeline again with €628m Autifony CNS deal
Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia
Intra-Cellular plans schizophrenia filing in 2018
Says lumateperone could provide additional benefits over existing treatments
Otsuka refiles ‘digital’ medicine for mental illness
Soluble sensor tracks drug ingestion and shares information with HCPs
